Sarda Proteins Stages Major Turnaround in Q1 FY27: Net Profit Reaches ₹165.97 Lakh on Solar Cell Demand

Sarda Proteins Limited today announced a stellar financial turnaround for the first quarter of fiscal year 2027 (Q1 FY27) ended June 30, 2026. Transitioning its business model to capture opportunities in the green energy sector, the company posted a substantial net profit, rebounding strongly from a net loss in the corresponding quarter of the previous fiscal year.

The performance highlights were reviewed by the Audit Committee and subsequently taken on record and approved by the Board of Directors at their respective meetings held today, July 15, 2026.

Strong Top-Line Growth Driven by Solar Transition

Following its strategic pivot into a single-segment business model focusing entirely on the "Renewable Energy Sector Solar Cell Products", Sarda Proteins has unlocked rapid commercial scaling:

Revenue from Operations: Climbed to ₹1,299.30 lakh (₹12.99 crore) for Q1 FY27, registering an impressive 18.61% YoY increase compared to ₹1,095.46 lakh in the first quarter of FY26. Sequentially, the company's core revenues skyrocketed from a meager ₹65.00 lakh in Q4 FY26.

Other Income: Rose sharply to ₹548.10 lakh, compared to ₹0.08 lakh in Q1 FY26 and ₹24.31 lakh in Q4 FY26.

Total Revenue: Reached ₹1,847.40 lakh, up 68.63% YoY from ₹1,095.54 lakh in the corresponding quarter last year.

Operational Expenditure and Key Cost Drivers

Total expenses for the quarter stood at ₹1,626.10 lakh, compared to ₹1,144.88 lakh in Q1 FY26. This increase reflects the logistical and input costs associated with scaled-up product distribution:

Purchase of Stock-in-Trade: Decreased to ₹970.32 lakh from ₹1,128.54 lakh in Q1 FY26, highlighting better sourcing optimization and lower raw material procurement drag.

Employee Benefit Expenses: Stood at ₹12.15 lakh, compared to ₹0.75 lakh in the year-ago period.

Other Expenses: Increased to ₹643.63 lakh against ₹15.59 lakh in Q1 FY26.

Finance Costs & Depreciation: The company reported nil finance costs and zero depreciation during the three-month period under review.

From Loss to Profit: Bottom-Line Performance

The strategic shift to higher-margin renewable energy products directly corrected the company's profitability curve:

Profit Before Tax (PBT): Logged at ₹221.30 lakh for Q1 FY27, reversing a severe standalone Net Loss Before Tax of ₹(49.34) lakh in Q1 FY26. Sequentially, PBT grew by 161.92% from ₹84.49 lakh in Q4 FY26.

Tax Provisions: The company set aside ₹55.33 lakh under current tax expenses for the quarter. No deferred tax provisions were made.

Net Profit After Tax (PAT): Came in at ₹165.97 lakh, marking a massive recovery from the Net Loss of ₹(49.34) lakh posted in Q1 FY26. Sequentially, net profit expanded by 96.44% over the ₹84.49 lakh registered in Q4 FY26.

Total Comprehensive Income: Settled at ₹165.97 lakh, with no adjustments reported under other comprehensive income.

Share Capital, EPS, and Investor Relations:

Reflecting the sharp earnings turnaround, basic and diluted Earnings Per Share (EPS) bounded back to a positive ₹1.85 per share (face value of ₹10 each), climbing from a negative EPS of ₹(2.86) in Q1 FY26 and ₹0.94 in Q4 FY26.

The company's paid-up equity share capital stood at ₹89.759 lakh (consisting of shares with a face value of ₹10 each), expanding from ₹17.259 lakh in the year-ago quarter.

Significantly bolstering investor confidence alongside the robust financial results, Sarda Proteins reported nil investor complaints received during the quarter ended June 30, 2026, with zero grievances pending resolution.

Source : Equity Bulls

Keywords

SardaProteins Q1FY27 Q1FY2027 ResultUpdate